The Critical Path Institute (AZ, USA) have announced support from the European Medicines Agency (London, UK) for the measurement of glutamate dehydrogenase as a biomarker of hepatocellular live injury.
Improved efficiency in neonatal diagnostics promised with the launch of a new device from PerkinElmer Inc (MA, USA).
Wacker Biotech GmbH (Jena, Germany) have announced that they will manufacture the active ingredient in the drug Retavase®. This drug has obtained FDA approval to treat acute myocardial infarction in adults.
Mass spectrometry based metabolomics: a novel analytical technique for detecting metabolic syndrome?
This editorial discusses the use of mass spectrometry metabolomics as a diagnositic tool for detecting metabolic syndrome. Learn more in this article from Bioanalysis.
In this commentary, Melanie Anderson discusses the use of paper-based dried sampling technologies and how they can provide opportunities to collect biological samples in the dried state, which involves significantly smaller sample volumes than traditional sample collection approaches.
In this editorial, the author discusses paper-based assays as an emerging technology in bioanalysis, as well as point-of care diagnostics and treatment.
The Good Clinical Laboratory Practice accreditation will enable the company to extend its proteomic services to the analysis of clinical trial samples.
A novel optical biosensor has shown potential as a cheap and easy alternative to current diagnostic techniques.
Researchers have identified the DAG peptide as a potential biomarker for Alzheimer’s disease development.
Researchers have published a new technique for the rapid and accurate identification of fentanyl, as well as a vast number of other drugs of abuse.